Plasma pTau and GFAP are associated with subjective cognitive decline and memory concerns in the remote, digital Brain Health Registry cohort

Abstract

Background: Plasma‐based biomarkers have recently shown great potential for identifying AD in early symptomatic stages. Subjective Cognitive Decline (SCD), defined as self‐report of worsening cognition, may also be an early symptomatic stage on the AD clinical continuum.